The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
Metrics: PDF 2122 views | HTML 1918 views | ?
Haitao Yang1,*, Huijuan Chen1,*, Shuimei Luo1, Lina Li1, Sijing Zhou1, Ruifen Shen1, Heng Lin1,2, Xianhe Xie1
1Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China
2Department of Oncology, Fuzhou Pulmonary Hospital, Fuzhou, Fujian 350008, China
*These authors are contributed equally to this work
Xianhe Xie, email: [email protected]
Keywords: PD-L1, EGFR, ALK, KRAS, NSCLC
Received: November 15, 2016 Accepted: February 13, 2017 Published: February 22, 2017
Objectives: This study aimed to evaluate the correlation between positive PD-L1 expression and driver gene mutations in NSCLC and to seek preliminary evidence in favor of the strategy of PD-L1 inhibitors plus targeted agents.
Results: The overall analyses revealed that positive PD-L1 expression had a significant relationship with KRAS status (RR = 1.26; 95% CI, 1.06−1.50, P = 0.010), but no correlation with clinical characteristics (gender, smoking status, histological types), driver gene status (EGFR, ALK) and overall survival (OS): male versus female (RR = 1.16; 95% CI, 0.95−1.42; P = 0.15), never smoking versus former/current smoking (RR = 0.79; 95% CI, 0.56−1.11; P = 0.17), adenocarcinoma versus non-adenocarcinoma (RR = 0.94; 95% CI, 0.63−1.41; P = 0.77), EGFR mutation versus EGFR wild type (RR = 0.74; 95% CI, 0.52−1.06; P = 0.10), ALK positive versus ALK negative (RR = 1.02; 95% CI, 0.75−1.38; P = 0.91), OS of positive PD-L1 expression versus that of negative PD-L1 expression (HR = 1.31, 95% CI, 0.90−1.90; P = 0.15), respectively. Noteworthily, subgroup analyses exhibited that in Chinese cohort studies, positive PD-L1 expression was significantly correlated with OS (HR = 1.75, 95% CI, 1.36−2.24, P < 0.0001); and in the studies using PD-L1 monoclonal antibodies (McAbs), positive PD-L1 expression was significantly correlated with KRAS mutation (RR = 1.32, 95% CI, 1.06−1.65, P = 0.01) and EGFR mutation (RR = 0.51, 95% CI, 0.28−0.93, P = 0.03).
Materials and Methods: After thoroughly searching PubMed, EMBASE and Cochrane Library databases, 11 relevant studies incorporating 3128 cases were identified. The pooled data were analyzed via Review manager 5.3 software.
Conclusions: PD-L1 inhibitors probably was a potential promising option to manage advanced NSCLC harboring KRAS mutation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.